Stock

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

17/03/2025
admin


Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer#Akeso039s #Penpulimab #Receives #NMPA #Approval #FirstLine #Treatment #Nasopharyngeal #Cancer